145 related articles for article (PubMed ID: 8909325)
1. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease.
Heikens J; Behrendt H; Adriaanse R; Berghout A
Cancer; 1996 Nov; 78(9):2020-4. PubMed ID: 8909325
[TBL] [Abstract][Full Text] [Related]
2. [Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
Soriano Guillén L; Muñoz Calvo MT; Pozo Román J; Contra Gómez T; Buño Soto M; Argente Oliver J
An Esp Pediatr; 2000 Oct; 53(4):318-23. PubMed ID: 11083980
[TBL] [Abstract][Full Text] [Related]
3. Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran.
Rafsanjani KA; Faranoush M; Hedayatiasl AA; Vossough P
Saudi Med J; 2007 Nov; 28(11):1690-3. PubMed ID: 17965791
[TBL] [Abstract][Full Text] [Related]
4. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM
Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817
[TBL] [Abstract][Full Text] [Related]
5. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.
Clark ST; Radford JA; Crowther D; Swindell R; Shalet SM
J Clin Oncol; 1995 Jan; 13(1):134-9. PubMed ID: 7799013
[TBL] [Abstract][Full Text] [Related]
6. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
7. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
van den Berg H; Furstner F; van den Bos C; Behrendt H
Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
[TBL] [Abstract][Full Text] [Related]
8. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.
Viviani S; Santoro A; Ragni G; Bonfante V; Bestetti O; Bonadonna G
Eur J Cancer Clin Oncol; 1985 May; 21(5):601-5. PubMed ID: 2408897
[TBL] [Abstract][Full Text] [Related]
9. Gonadal function in prepubertal boys following treatment for Hodgkin's disease.
Dhabhar BN; Malhotra H; Joseph R; Garde S; Bhasin S; Sheth A; Advani SH
Am J Pediatr Hematol Oncol; 1993 Aug; 15(3):306-10. PubMed ID: 8328644
[TBL] [Abstract][Full Text] [Related]
10. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence.
Brämswig JH; Heimes U; Heiermann E; Schlegel W; Nieschlag E; Schellong G
Cancer; 1990 Mar; 65(6):1298-302. PubMed ID: 2106384
[TBL] [Abstract][Full Text] [Related]
11. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
[TBL] [Abstract][Full Text] [Related]
12. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence.
Bordallo MA; Guimarães MM; Pessoa CH; Carriço MK; Dimetz T; Gazolla HM; Dobbin J; Castilho IA
J Pediatr Endocrinol Metab; 2004 Jun; 17(6):879-87. PubMed ID: 15270406
[TBL] [Abstract][Full Text] [Related]
13. [Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study].
Hassel JU; Brämswig JH; Schlegel W; Schellong G
Klin Padiatr; 1991; 203(4):268-72. PubMed ID: 1942933
[TBL] [Abstract][Full Text] [Related]
14. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience.
Ortin TT; Shostak CA; Donaldson SS
Int J Radiat Oncol Biol Phys; 1990 Oct; 19(4):873-80. PubMed ID: 2211255
[TBL] [Abstract][Full Text] [Related]
15. [Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993].
Naccache P; Decaudin D; Koscielny S; Bendahmane B; Auger J; Munck JN
Bull Cancer; 1996 Apr; 83(4):307-14. PubMed ID: 8680082
[TBL] [Abstract][Full Text] [Related]
16. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.
Anselmo AP; Cartoni C; Bellantuono P; Maurizi-Enrici R; Aboulkair N; Ermini M
Haematologica; 1990; 75(2):155-8. PubMed ID: 1694156
[TBL] [Abstract][Full Text] [Related]
17. Testicular dysfunction in Hodgkin's disease before and after treatment.
Viviani S; Ragni G; Santoro A; Perotti L; Caccamo E; Negretti E; Valagussa P; Bonadonna G
Eur J Cancer; 1991; 27(11):1389-92. PubMed ID: 1835853
[TBL] [Abstract][Full Text] [Related]
18. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
[TBL] [Abstract][Full Text] [Related]
19. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease.
Sherins RJ; Olweny CL; Ziegler JL
N Engl J Med; 1978 Jul; 299(1):12-6. PubMed ID: 661845
[TBL] [Abstract][Full Text] [Related]
20. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
